Praxis Precision Medicines to present analyses from Essential1 study

Praxis Precision Medicines will be presenting analyses highlighting patient-focused endpoints from its Essential1 study of ulixacaltamide in essential tremor at The International Parkinson and Movement Disorder Society’s International Congress of Parkinson’s Disease and Movement Disorders, taking place in Copenhagen, Denmark. Presentation Details: Patient-Focused, Clinically Meaningful Endpoints as Evidence of Improved Outcomes and Durability of Effect Following Ulixacaltamide Treatment in Adults with Essential Tremor: Findings from Essential1: Summary: While the concept of clinically meaningful change has been extensively studied in other movement disorders and neurological conditions, this has not been evaluated in ET. This study represents the first time a Meaningful Score Difference has been defined in ET using a large patient dataset and a focus on measures determined to be most meaningful to patients. In this poster presentation, Praxis will highlight modified Activities of Daily Living 11 as a reliable, patient-focused clinical outcome assessment for measuring ulixacaltamide efficacy and durability of effect, with important decision-making implications for ET therapies.